NEW YORK, May 03, 2019 (GLOBE NEWSWIRE) — Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, confirms that the Company met with the U.S. Food & Drug Administration (FDA) on May 3, 2019 as expected. The Type A meeting was held to discuss the points raised in the Complete...
Category: News
Melinta Therapeutics to Report First Quarter 2019 Financial Results on May 9, 2019
MORRISTOWN, N.J., May 02, 2019 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced it intends to release its first quarter 2019 financial results on May 9, 2019, after the close of the U.S. financial markets. Melinta...
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, May 01, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 126,500 ordinary shares of Nabriva Therapeutics as inducements to five newly-hired employees. The...
SCYNEXIS to Present Data at ACOG 2019 Further Demonstrating the Favorable Profile of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)
JERSEY CITY, N.J., May 1, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that data further demonstrating the potential for ibrexafungerp to treat VVC will be presented in one oral and two ePoster presentations at the 2019 American College of Obstetrics and Gynecology...
Motif Bio Signs Agreement with Lamellar Biomedical
Evaluation of Iclaprim in Combination with LMS-611 for Cystic Fibrosis Lung Infections NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) — Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with Lamellar Biomedical Limited (Lamellar) under which Motif Bio will conduct an...
Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for Intravenous CONTEPO™ (fosfomycin) for injection
Issues related to facility inspections and manufacturing deficiencies at one contract manufacturer Conference call and webcast tomorrow at 8:00 a.m. EDT DUBLIN, Ireland, April 30, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced today that it received...
Paratek Pharmaceuticals to Report First Quarter 2019 Financial Results on May 8, 2019
BOSTON, April 30, 2019 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcast on Wednesday, May 8, 2019 at 4:30 p.m. EDT to report its first quarter ended March 31,...
Qpex Biopharma Licenses Polymyxin Antimicrobial Program from Monash University to Address Drug-Resistant Infections
SAN DIEGO, April 30, 2019 /PRNewswire/ — Qpex Biopharma today announced the closing of a license agreement from Monash University providing Qpex a portfolio of next-generation polymyxin antimicrobials focused against highly drug-resistant gram-negative pathogens. The exclusive license includes worldwide rights to develop and commercialize polymyxin antimicrobials in multiple territories. The polymyxin class of antibiotics, including the drug...
Block Listing Interim Review
BLOCK LISTING SIX MONTHLY RETURN (Note: Italicised terms have the same meaning as given in the Listing Rules.) Date: 29 April 2019 Name of applicant: Summit Therapeutics plc Name of scheme: 2005 EMI Scheme Period of return: From: 30 Sep 2018 To: 31 Mar 2019 Balance of unallotted securities under scheme(s) from previous return: 4,402,293...
Motif Bio plc: Notice of Annual General Meeting
NEW YORK, April 26, 2019 (GLOBE NEWSWIRE) — Motif Bio plc (“Motif Bio” or the “Company”) (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that its notice of its Annual General Meeting (AGM) have been posted to shareholders and will shortly be available for download from the Company’s website at...